AZLI 75 mg three times a day
Idiopathic Pulmonary Fibrosis · ANZCTR
Clinical trials
1
Mechanism
ANZCTR
Developer
Gilead Sciences
Overview
AZLI 75 mg three times a day is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via anzctr. It appears in 1 tracked IPF clinical trial.
AZLI 75 mg three times a day clinical trials
Explore related
Medical disclaimer. This page summarizes research about AZLI 75 mg three times a day for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.